Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neuren Pharmaceutica (NURPF)

Neuren Pharmaceutica (NURPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.40
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6440 +5.84%
on 12/16/19
1.7400 unch
on 01/07/20
+0.1300 (+8.07%)
since 12/06/19
3-Month
1.5500 +12.26%
on 10/11/19
1.8100 -3.87%
on 11/14/19
+0.3000 (+20.83%)
since 10/07/19
52-Week
0.7400 +135.14%
on 04/25/19
1.8100 -3.87%
on 11/14/19
+0.6410 (+58.33%)
since 01/02/19

Most Recent Stories

More News
FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes

Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren's NNZ-2591 for the treatment of Angelman syndrome, Phelan-McDermid...

NURPF : 1.7400 (+1.75%)
NEU : 471.22 (+0.21%)
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Neuren Pharmaceuticals Limited (ASX: NEU), and Rettsyndrome.org (RSO) announced today that the positive results from a Phase 2 study conducted...

NURPF : 1.7400 (+1.75%)
ACAD : 43.43 (-2.54%)
NEU : 471.22 (+0.21%)
Trade NURPF with:

Key Turning Points

2nd Resistance Point 1.7400
1st Resistance Point 1.7400
Last Price 1.7400
1st Support Level 1.7400
2nd Support Level 1.7400

See More

52-Week High 1.8100
Last Price 1.7400
Fibonacci 61.8% 1.4013
Fibonacci 50% 1.2750
Fibonacci 38.2% 1.1487
52-Week Low 0.7400

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar